We have the pleasure inviting you to the unique launch event of Tecentriq ® (atezolizumab)▼ & Alecensa ® (alectinib)▼ in non-small cell lung cancer.
19.00 - 19.45 Welcome and catering
19.45 - 20.30: Introducing the Cancer Immunity Cycle
20.30- 21.30: Exploring cancer immunotherapy in non-small cell lung cancer
21.30 - 22.15: Exploring ALK inhibition and New options for ALK+
22.15 - 22.30: Closing summary
R.E. Dr Chr Lenaerts – BE/LUN/0118/0007 - 24/01/2018
ALK = anaplastic lymphoma kinase
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.